In order to address these aims, we combined florbetapir-PET for the measurement of myelin with longitudinal assessment of fibrillar tau accumulation in a sample of clinically well-characterized patients with biomarker evidence of AD [18]. The gene discussed is MAPT; the disease is Alzheimer disease.